Amgen Announced New Lumakras Plus Vectibix Data In Patients With KRAS G12c-mutated Metastatic Colorectal Cancer
Portfolio Pulse from Charles Gross
Amgen (NASDAQ:AMGN) announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS in combination with Vectibix. Both doses demonstrated a statistically significant superiority in progression-free survival over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The results were presented at the ESMO 2023 Congress and published in the New England Journal of Medicine.
October 22, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's successful Phase 3 trial results for LUMAKRAS and Vectibix could potentially boost the company's stock in the short term.
The successful trial results for LUMAKRAS and Vectibix, which demonstrated significant superiority in progression-free survival for patients with metastatic colorectal cancer, could potentially lead to increased sales and revenue for Amgen. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100